An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Steegmann, Juan Luisca
- dc.contributor.author Colomer Pujol, Dolorsca
- dc.contributor.author Gómez-Casares, Maria-Teresaca
- dc.contributor.author García-Gutiérrez, Valentínca
- dc.contributor.author Ortí, Guillermoca
- dc.contributor.author Ramírez-Payer, Angelca
- dc.contributor.author Olavarria, Eduardoca
- dc.contributor.author Vall-llovera, Ferránca
- dc.contributor.author Giraldo, Pilarca
- dc.contributor.author Conde, Eulogioca
- dc.contributor.author Vallansot, Rolandoca
- dc.contributor.author López-Lorenzo, Jose Luisca
- dc.contributor.author Palomera, Luisca
- dc.contributor.author Alvarez-Larrán, Albertoca
- dc.contributor.author Conesa, Venancioca
- dc.contributor.author Bautista, Guiomarca
- dc.contributor.author Casas, Lauraca
- dc.contributor.author Giles, Frankca
- dc.contributor.author Hochhaus, Andreasca
- dc.contributor.author Casado-Montero, Luis Felipeca
- dc.date.accessioned 2018-06-12T07:38:20Z
- dc.date.available 2018-06-12T07:38:20Z
- dc.date.issued 2017
- dc.description.abstract PURPOSE: This study was aimed to analyze the association of very early molecular response to nilotinib with the achievement of deep molecular response (MR4) at 18 months. We hypothesized that the BCR-ABL1 levels during the first 3 months of therapy, and the kinetics of their descent in this period, could be predictive of deep molecular response thereafter. METHODS: This substudy of the ENEST1st trial included 60 patients with chronic myeloid leukemia in chronic phase treated with front-line nilotinib, and BCR-ABL1IS levels were measured using GUS as the control gene. The analysis included seven time points during the first trimester of treatment (baseline and fortnightly thereafter). RESULTS: The rates of MMR at 12 months, and of MR4 at 18 months (primary variable of the study), were 70 and 41%, respectively, similar to those obtained in the core study. BCR-ABL1IS ≤10% was achieved at 1, 1.5, 2 and 3 months in 50, 70, 83 and 93% of the patients, respectively. The observed shape of the BCR-ABL1IS descent was biphasic, with a faster slope during the first trimester and a median halving time (HT) of 11 days, the shortest reported in the literature. An HT ≤13 days was predictive of MMR at 12 months and MR4 at 18 months. CONCLUSIONS: The association of a shorter HT with response provides a rationale for exploring very early kinetics patterns in all patients treated with potent TKIs such as nilotinib.
- dc.format.mimetype application/pdf
- dc.identifier.citation Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A. et al. An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2017 Oct;143(10):2059-2066. DOI: 10.1007/s00432-017-2445-z
- dc.identifier.doi http://dx.doi.org/10.1007/s00432-017-2445-z
- dc.identifier.issn 0171-5216
- dc.identifier.uri http://hdl.handle.net/10230/34874
- dc.language.iso eng
- dc.publisher SpringerOpenca
- dc.relation.ispartof Journal of Cancer Research and Clinical Oncology. 2017 Oct;143(10):2059-66
- dc.rights Copyright © Springer-Verlag Berlin Heidelberg 2017
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.keyword Chronic myeloid leukemia
- dc.subject.keyword ENEST1st
- dc.subject.keyword Nilotinib
- dc.subject.other Leucèmia -- Aspectes genètics
- dc.title An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phaseca
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion